Cargando…
Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients
BACKGROUND: Coronavirus disease 2019 (COVID-19) causing severe acute respiratory distress syndrome caused by coronavirus 2 (SARS-CoV-2) still has no solid effective therapy. From previous studies, dexamethasone has led to a decrease in mortality in patients who required oxygen supplementation mainly...
Autores principales: | Saeed, Mohammed Abdel Monem, Mohamed, Alaa Hussein, Owaynat, Ahmed Hassan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853130/ https://www.ncbi.nlm.nih.gov/pubmed/35194371 http://dx.doi.org/10.1186/s43162-022-00113-z |
Ejemplares similares
-
Cholecalciferol level and its impact on COVID-19 patients
por: Saeed, Mohammed Abdel Monem, et al.
Publicado: (2022) -
Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS
por: Meduri, Gianfranco Umberto, et al.
Publicado: (2018) -
Dexamethasone/hydrocortisone/methylprednisolone: Disseminated cryptococcosis following off label use of dexamethasone, hydrocortisone and methylprednisolone: case report
Publicado: (2022) -
PULSED METHYLPREDNISOLONE USAGE IN ARDS DUE TO VIRAL PNEUMONIA
por: Szeto, C.H.
Publicado: (2019) -
Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease
por: Fatima, Syeda Arzinda, et al.
Publicado: (2020)